id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-335312-yp73z008	Bergsland, Emily K.	North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19	2020-05-19		.txt	text/plain	3409	168	41	Clinical decisions should be individualized between patients and their doctor to consider factors such as the likelihood and consequences of cancer progression if therapy is delayed, modified, or interrupted; whether or not the tumor is functional (making hormones that cause symptoms); and the patient's tolerance of treatment. Health care providers and patients will need to make individual determinations based on the potential harms of delaying needed cancer-related surgery, the specific situation at their hospital, and the increased risk to the patient from COVID-19 exposure. The decision to extend the interval between treatments and/or omit one or more cycles of therapy in a patient on PRRT will need to be made on a case-by-case basis (considering response and tolerability to date, COVID-19 risk factors, general clinical status, prior therapy, etc) balancing the potential consequences of cancer progression with the potential ramifications of COVID-19 infection.	./cache/cord-335312-yp73z008.txt	./txt/cord-335312-yp73z008.txt